Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution

被引：44

作者：

Gerloff, T ^{[1
]}

机构：

[1] Humboldt Univ, Charite Univ Med Ctr, Inst Clin Pharmacol, D-10098 Berlin, Germany

来源：

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2004年 / 369卷 / 01期

关键词：

pharmacogenetics; transmembrane transporters; drug disposition; polymorphisms; blood tissue barriers; uptake; efflux;

D O I：

10.1007/s00210-003-0813-5

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Active transport across biological membranes has become a noticeable factor in the absorption, distribution, and excretion of an increasing number of drugs. Different transmembrane transport systems including organic anion transporters (OATP, solute carrier family SLC21A), organic cation transporters (OCT, SLC22A), dipeptide transporters (PEPT, SLC15A), nucleoside transporters (CNT, SLC28A), monocarboxylate carriers (MCT, SLC2A), and members of the large ATP-binding cassette family (ABC, SLC3A) are involved in drug disposition. Genetic polymorphisms in transport proteins frequently occur and contribute to interindividual differences in the efficacy and safety of pharmatherapy. Currently, the most advanced research has been done on P-glycoprotein (ABCB1, SLC3A1.201.1). Knowledge of this transporter indicates that haplotype analysis rather than association with single nucleotide polymorphisms (SNPs) provides the most appropriate interpretation of pharmacogenetic data from drug transporters. This review gives an overview and update on the pharmacological impact of genetic variants in transmembrane transporters.

引用

页码：69 / 77

页数：9

共 77 条

[1]

ARNDT P, 2001, AM J PHYSIOL-RENAL, V281, P110

[2]

Avdeef Alex, 2001, Current Topics in Medicinal Chemistry, V1, P277, DOI 10.2174/1568026013395100

[3] Role of transport proteins in drug absorption, distribution and excretion [J].

Ayrton, A ;

Morgan, P .

XENOBIOTICA, 2001, 31 (8-9) :469-497

[4] Mammalian ABC transporters in health and disease [J].

Borst, P ;

Elferink, RO .

ANNUAL REVIEW OF BIOCHEMISTRY, 2002, 71 :537-592

[5]

Camenisch G, 1996, Pharm Acta Helv, V71, P309, DOI 10.1016/S0031-6865(96)00031-3

[6] Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects [J].

Cascorbi, I ;

Gerloff, T ;

Johne, A ;

Meisel, C ;

Hoffmeyer, S ;

Schwab, M ;

Schaeffeler, E ;

Eichelbaum, M ;

Brinkmann, U ;

Roots, I .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :169-174

[7] Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) rnRNA and hepatic induction of mrp3 by constitutive androstane receptor activators in rats [J].

Cherrington, NJ ;

Hartley, DP ;

Li, N ;

Johnson, DR ;

Klaassen, CD .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (01) :97-104

[8] OVEREXPRESSION OF A TRANSPORTER GENE IN A MULTIDRUG-RESISTANT HUMAN LUNG-CANCER CELL-LINE [J].

COLE, SPC ;

BHARDWAJ, G ;

GERLACH, JH ;

MACKIE, JE ;

GRANT, CE ;

ALMQUIST, KC ;

STEWART, AJ ;

KURZ, EU ;

DUNCAN, AMV ;

DEELEY, RG .

SCIENCE, 1992, 258 (5088) :1650-1654

[9] A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance [J].

Conrad, S ;

Kauffmann, HM ;

Ito, K ;

Leslie, EM ;

Deeley, RG ;

Schrenk, D ;

Cole, SPC .

PHARMACOGENETICS, 2002, 12 (04) :321-330

[10] Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution [J].

Conrad, S ;

Kauffmann, HM ;

Ito, K ;

Deeley, RG ;

Cole, SPC ;

Schrenk, D .

JOURNAL OF HUMAN GENETICS, 2001, 46 (11) :656-663

← 1 2 3 4 5 6 7 8 →